NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.51 +0.03 (+0.04%) GOLD FUTURES
2,322.50 -8.70 (-0.37%) DOW
38,877.58 +25.31 (+0.07%) Bitcoin GBP
50,524.19 -70.62 (-0.14%)
GH May 2024 12.500 call
| Previous close | 4.7100 |
| Open | 6.1500 |
| Bid | 5.9000 |
| Ask | 8.8000 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 4.7100 - 6.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
ZacksGuardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Business WireGuardant Health Surpasses 500 Peer-Reviewed Publications Milestone
PALO ALTO, Calif., May 07, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.
ZacksCurious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
